Veralox Therapeutics

Veralox Therapeutics is the industry leader in targeting the 12-Lipoxygenase (12-LOX) pathway, pioneering a new class of therapies to address some of the most persistent diseases in medicine. Our most advanced program is VLX-1005, a Phase 2 ready, first-in-class, selective, small-molecule 12-LOX inhibitor with orphan drug and fast track designation for the treatment of heparin-induced thrombocytopenia (HIT), with a commercial opportunity of over $1B (USD) at peak. Our second series, VLX-2000, is currently in preclinical development and shows potential in many inflammatory diseases including lupus, diabetic complications and T1D. For T1D we have data to support preservation of β-cells and slow the progression of disease. Based in Frederick, Maryland, the founders are leading domain experts and have backing from blue-chip venture investors, including Hatteras Venture Partners, Sanofi Ventures, Genesys Capital and the JDRF T1D fund.